Engineering and production of recombinant bovine pancreatic ribonuclease enzyme (RNase A) as a potential therapeutic

Document Type : Research Paper


1 Animal Science Department, Faculty of Agriculture, Ferdowsi University of Mashhad, Mashhad, Iran

2 Professor, Recombinant proteins research group, The research institute of biotechnology, Ferdowsi University of Mashhad, Mashhad, Iran

3 Animal Science Department, Faculty of Agriculture, University of Guilan, Rasht, Iran

4 Department of Animal Science, Faculty of Agriculture, Ferdowsi University of Mashhad, Mashhad, Iran


Immunotoxins are one of the most promising ways in therapeutic fields, specially cancer therapy which have a unique toxin-antibody structure, and kill the cancer cell by passing through the cell membrane and entering the target cell. The aim of this study was to engineer and design bovine pancreatic enzyme (RNase A) for to escape from ribonuclease inhibitor (RI) as a toxin segment in designing of immunotoxins used in therapeutic fields.
Materials and Methods
After bioinformatics investigation using PyMol software, engineering and substitution of target amino acid in wild gene coding RNase A sequence (K91A) were performed. The wild type and recombinant proteins in E.coli (BL21(D3) strain) were expressed and refolded, and then approved using SDS-PAGE. The purification of produced proteins was conducted using an immobilized-metal affinity chromatography for His-tagged proteins.
The results showed that the protein concentrations were 3 and 2.2 g/L for wild RNase A and recombinant enzyme. The hydrolysis activity measurement of the produced enzymes, in presence of different concentrations of RI, indicated that recombinant variant had lower sensitivity and higher catalytic activity in comparison with the wild enzyme. The results obtained from enzyme activity of recombinant enzyme compared to the wild enzyme, in presence or absence of RI, demonstrated that the interaction effect between RNase A and RI can be disrupted by manipulation of amino acids involved in this interaction.
In respect to the current results, it was concluded that RNase A enzyme can be used as a promising drug in engineering and production of immunotoxins.


Akbari B, Farajnia S, Ahdi Khosroshahi S et al. (2017) Immunotoxins in cancer therapy: Review and update. Int Rev Immunol 36, 207-219.
Ardelt W, Ardelt B, Darzynkiewicz Z (2009) Ribonucleases as potential modalities in anticancer therapy. Eur J Pharmacol 625, 181-189.
Borriello M, Laccetti P, Terrazzano G et al. (2011) A novel fully Human antitumour immunoRNase targeting ErbB2-positive tumours. Br J Cancer 104, 1716-1723.
Cuchillo CM, Nogués MV, Raines RT (2011) Bovine pancreatic ribonuclease: fifty years of the first enzymatic reaction mechanism. Biochem 50, 7835-7841.
Dickson KA, Haigis MC, Raines RT (2005) Ribonuclease inhibitor: structure and function. Prog Nucleic Acid Res Mol Biol 80, 349-374.
Findlay D, Herries DG, Mathias AP et al. (1961) The active site and mechanism of action of bovine pancreatic ribonuclease. Nature 190, 781–784.
Genscript, Piscataway, NJ, USA (
Gotte G, Laurents DV, Merlino A et al. (2013) Structural and functional relationships of natural and artificial dimeric bovine ribonucleases: new scaffolds for potential antitumor drugs. FEBS Lett 587, 3601-3608.
Gotte G, Menegazzi M (2019) Biological activities of secretory RNases: Focus on their oligomerization to design antitumor drugs. Front Immunol 10, 2626.
Johnson RJ, McCoy JG, Bingman CA et al. (2007) Inhibition of human pancreatic ribonuclease by the human ribonuclease inhibitor protein. J Mol Biol 368, 434-449.
Jordaan S, Akinrinmade OA, Nachreiner T et al. (2018) Updates in the development of immunoRNases for the selective killing of tumor cells. Biomedicines 6, 28.
Kimiz-Gebologlu I, Gulce-Iz S, Biray-Avci C (2018) Monoclonal antibodies in cancer immunotherapy. Mol Biol Rep 45, 2935‐2940.
Lee I (2008) Ranpirnase (Onconase), a cytotoxic amphibian ribonuclease, manipulates tumour physiological parameters as a selective killer and a potential enhancer for chemotherapy and radiation in cancer therapy. Expert Opin Biol Ther 8, 813-827.
Li M, Liu ZS, Liu XL et al. (2017) Clinical targeting recombinant immunotoxins for cancer therapy. Onco Targets Ther 10, 3645‐3665.
Mohammadabadi MR, Mozafari MR (2019) Enhanced efficacy and bioavailability of thymoquinone using nanoliposomal dosage form. J Drug Delivery Sci Technol 47, 445–453.
Pucci C, Martinelli C, Ciofani G (2019) Innovative approaches for cancer treatment: current perspectives and new challenges. Ecancermedicalscience 13, 961.
Raines RT (2004) Active Site of Ribonuclease A. In: Artificial Nucleases (1st edn). Zenkova MA (eds). Springer, Berlin, Heidelberg. pp. 19-32.
Rutkoski TJ, Kink JA, Strong LE (2010) Antitumor activity of ribonuclease multimers created by site-specific covalent tethering. Bioconjug Chem 21, 1691-1702.
Schirrmann T, Frenzel A, Linden L et al. (2014) Evaluation of human pancreatic RNase as effector molecule in a therapeutic antibody platform. MAbs 6, 367–380.
Sun M, Sun L, Sun D et al. (2018) Targeted delivery of immuno-RNase may improve cancer therapy. Cancer Cell Int 18, 58.
Taherian E, Mohammadi E, Jahanian-Najafabadi A et al. (2019) Cloning, optimization of periplasmic expression and purification of recombinant granulocyte macrophage-stimulating factor in Escherichia coli BL21 (DE3). Adv Biomed Res 8, 71.
PyMol Software (2016) The PyMOL molecular graphics system, Version 1.8 Schrödinger, LLC, NY, USA.
World Health Organization (2018) Latest global cancer data: International Agency for Research on Cancer. Geneva, Switzerland.